Digitoxin induces apoptosis in cancer cells by inhibiting nuclear factor of activated T-cells-driven c-MYC expression

Journal of Carcinogenesis

Volumn 12, Issue , 2013, Pages

  Yang, Qing ^a   Dalgard, Clifton ^a   Eidelman, Ofer ^a   Jozwik, Catherine ^a   Pollard, Bette ^b   Srivastava, Meera ^a   Pollard, Harvey ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b US Equal Employment Opportunity Commission   (United States)

Author keywords

c MYC; Cardiac glycosides; nuclear factor of activated T cells

Indexed keywords

CASPASE 3; DIGITOXIN; MESSENGER RNA; MYC PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; TRANSCRIPTION FACTOR NFAT2; TRANSCRIPTION FACTOR NFAT3; TRANSCRIPTION FACTOR NFAT4; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; ONCOGENE C MYC; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN DNA INTERACTION;

EID: 84893027632     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.112268     Document Type: Article

References (51)

1. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses 1999;53:543-8. (Pubitemid 30064132)
2. Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs 2001;12:475-83. (Pubitemid 32643092)
3. López-Lázaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortés F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 2005;68:1642-5. (Pubitemid 41789573)
4. Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, Carrillo-Hernandez JF, Pastelín-Hernandez G, Picazo-Picazo O, et al. Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. Eur J Pharmacol 2006;534:71-6. (Pubitemid 43384185)
5. Sreenivasan Y, Raghavendra PB, Manna SK. Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. J Clin Immunol 2006;26:308-22. (Pubitemid 44051378)
6. Inada A, Nakanishi T, Konoshima T, Kozuka M, Tokuda H, Nishino H, et al. Anti-tumor promoting activities of natural products. II. Inhibitory effects of digitoxin on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors. Biol Pharm Bull 1993;16:930-1. (Pubitemid 23329808)
7. Afaq F, Saleem M, Aziz MH, Mukhtar H. Inhibition of 12-O-tetradecanoyl phorbol-13-acetate-induced tumor promotion markers in CD-1 mouse skin by oleandrin. Toxicol Appl Pharmacol 2004;195:361-9. (Pubitemid 38338657)
8. Nasu S, Milas L, Kawabe S, Raju U, Newman R. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett 2002;185:145-51.
9. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006;66:5867-74. (Pubitemid 43927141)
10. Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, et al. Nucleolus and c-Myc: Potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 2008;7:1285-96.
11. Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, et al. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 2006;5:391-9.
12. Svensson A, Azarbayjani F, Bäckman U, Matsumoto T, Christofferson R. Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res 2005;25:207-12. (Pubitemid 40470112)
13. Antczak C, Kloepping C, Radu C, Genski T, Müller-Kuhrt L, Siems K, et al. Revisiting old drugs as novel agents for retinoblastoma: In vitro and in vivo antitumor activity of cardenolides. Invest Ophthalmol Vis Sci 2009;50:3065-73.
14. Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B. Cardiac glycosides and breast cancer, revisited. N Engl J Med 1982;306:484. (Pubitemid 12171682)
15. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 2001;1:11.
16. Srivastava M, Eidelman O, Zhang J, Paweletz C, Caohuy H, Yang Q, et al. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci USA 2004;101:7693-8. (Pubitemid 38658091)
17. Tabary O, Boncoeur E, de Martin R, Pepperkok R, Clément A, Schultz C, et al. Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells. Cell Signal 2006;18:652-60. (Pubitemid 43113295)
18. Manna SK, Sah NK, Newman RA, Cisneros A, Aggarwal BB. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res 2000;60:3838-47. (Pubitemid 32204576)
19. Yang Q, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy H, et al. Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci USA 2005;102:9631-6. (Pubitemid 40981732)
20. Thompson EB. The many roles of c-Myc in apoptosis. Annu Rev Physiol 1998;60:575-600. (Pubitemid 28157887)
21. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca 2+/calcineurin signaling pathway. EMBO J 2006;25:3714-24. (Pubitemid 44264881)
22. Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004;6:195-206. (Pubitemid 38657075)
23. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci 1996;21:83-6. (Pubitemid 26088517)
24. Xu Y, Nguyen Q, Lo DC, Czaja MJ. C-myc-Dependent hepatoma cell apoptosis results from oxidative stress and not a deficiency of growth factors. J Cell Physiol 1997;170:192-9. (Pubitemid 27076220)
25. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006;21:509-19. (Pubitemid 43228006)
26. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: Nodes of coordination in immune signaling networks. Nat Immunol 2009;10:348-55.
27. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)
28. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84. (Pubitemid 40215841)
29. Köenig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G, et al. NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 2010;138:1189-99.e1-2.
30. Singh G, Singh SK, König A, Reutlinger K, Nye MD, Adhikary T, et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010;285:27241-50.
31. Wu W, Misra RS, Russell JQ, Flavell RA, Rincón M, Budd RC. Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3. J Biol Chem 2006;281:10682-90. (Pubitemid 43855489)
32. Prassas I, Paliouras M, Datti A, Diamandis EP. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: Implications for cancer therapies. Clin Cancer Res 2008;14:5778-84.
33. Raghavendra PB, Sreenivasan Y, Ramesh GT, Manna SK. Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. Apoptosis 2007;12:307-18. (Pubitemid 46169911)
34. Chuvpilo S, Jankevics E, Tyrsin D, Akimzhanov A, Moroz D, Jha MK, et al. Autoregulation of NFATc1/A expression facilitates effector T cells to escape from rapid apoptosis. Immunity 2002;16:881-95. (Pubitemid 34786486)
35. Zhou B, Cron RQ, Wu B, Genin A, Wang Z, Liu S, et al. Regulation of the murine Nfatc1 gene by NFATc2. J Biol Chem 2002;277:10704-11. (Pubitemid 34968198)
36. Fretz JA, Shevde NK, Singh S, Darnay BG, Pike JW. Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase. Mol Endocrinol 2008;22:737-50. (Pubitemid 351397799)
37. Walczak-Drzewiecka A, Ratajewski M, Wagner W, Dastych J. HIF-1alpha is up-regulated in activated mast cells by a process that involves calcineurin and NFAT. J Immunol 2008;181:1665-72.
38. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008;105:19579-86.
39. Arispe N, Diaz JC, Simakova O, Pollard HB. Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels. Proc Natl Acad Sci USA 2008;105:2610-5. (Pubitemid 351520561)
40. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca 2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000;60:3807-12. (Pubitemid 32204572)
41. Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem 2004;279:10822-8. (Pubitemid 38372695)
42. Yeh JY, Huang WJ, Kan SF, Wang PS. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol 2001;166:1937-42. (Pubitemid 32953461)
43. Huang YT, Chueh SC, Teng CM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 2004;67:727-33.
44. Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008;10:198-206. (Pubitemid 351328589)
45. Biroccio A, Amodei S, Antonelli A, Benassi B, Zupi G. Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem 2003;278:35693-701. (Pubitemid 37102344)
46. Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, et al. Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 2006;5:167-81. (Pubitemid 43843828)
47. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318-30. (Pubitemid 44311040)
48. Dürst M, Croce CM, Gissmann L, Schwarz E, Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 1987;84:10704.
49. Lazo PA, DiPaolo JA, Popescu NC. Amplification of the integrated viral transforming genes of human papillomavirus 18 and its 5′-flanking cellular sequence located near the myc protooncogene in HeLa cells. Cancer Res 1989;49:4305-10. (Pubitemid 19207277)
50. Monticelli S, Rao A. NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. Eur J Immunol 2002;32:2971-8. (Pubitemid 35238190)
51. Jones EA, Sun D, Kobierski L, Symes AJ. NFAT4 is expressed in primary astrocytes and activated by glutamate. J Neurosci Res 2003;72:191-7. (Pubitemid 36389885)